Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ad Warning Letters On Track For Significant Increase In 2005

Executive Summary

FDA is on track for a significant increase in the number of warning letters issued to drug marketers for advertising violations in 2005

You may also be interested in...



FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information

An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information

FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information

An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information

DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles

FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel